Par Pharmaceutical Terminates Partnership With Advancis Pharmaceutical
The decision to terminate the partnership follows the recent release of results from Advancis' Amoxicillin PULSYS Phase III clinical trials.
SPRING VALLEY, N.Y. – August 03, 2005 – Par Pharmaceutical Companies, Inc. today announced that it has terminated its partnership agreement with Advancis Pharmaceutical Corporation. The decision to terminate the partnership follows the recent release of results from Advancis' Amoxicillin PULSYS Phase III clinical trials. In both clinical trials, the Amoxicillin PULSYS product failed to achieve the desired microbiological and clinical endpoints. In 2004, Par entered into the agreement with Advancis to develop and market a novel formulation of the antibiotic amoxicillin.
Under the terms of the agreement, Par made quarterly payments to Advancis to fund the development of the Amoxicillin PULSYS product. Par's $4.75 million payment for the third quarter of 2005 fulfills Par's final obligation to Advancis. By terminating the partnership at this time, Par is no longer responsible for the fourth-quarter installment of $4.75 million, which would have represented Par's final payment to Advancis. If Advancis succeeds in developing and marketing any amoxicillin PULSYS product, Par will be reimbursed from the proceeds for up to half of its development expenses.
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. The company is also developing an additional line of branded pharmaceutical products for specialty markets, the first of which is Megace(R) ES. Par currently manufactures, markets or licenses more than 90 prescription drugs. For press release and other company information, visit http://www.parpharm.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
